Market Intelligence, Clinical Progress, and High-Purity Reagents for PTEN-Deficient Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PIK3CB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PIK3CB (p110 beta) Recombinant Protein / Complex High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PIK3CB Products |
| Gene Delivery | PIK3CB Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PIK3CB Products |
| Benchmark Ab | Anti-PIK3CB Benchmark Antibody Recombinant positive control for target engagement. |
View PIK3CB Products |
| Validator | PIK3CB siRNA Set For knockdown verification and specificity checks. |
View PIK3CB Products |
| Related Target A | PIK3CA (PI3K p110 Alpha) Critical for counter-screening to ensure isoform selectivity and avoid metabolic toxicity. |
View PIK3CA Products |
| Related Target B | PTEN Tumor suppressor loss creates synthetic lethality and reliance on PIK3CB signaling. |
View PTEN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Cross-Reactivity (Alpha vs. Beta) | Comprehensive PI3K subfamily homolog panel available; strictly verified by mass spec and sequence analysis. |
| Complex Formation & Stability | Co-expressed p110 beta/p85 regulatory subunit complexes designed for accurate biochemical kinase assays. |
| Lack of Validated Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives in Phenotypic Screens | Sequence-verified siRNA included for precise pathway knockdown validation. |
Live PIK3CB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PIK3CB therapeutics is intensifying, with major players shifting focus from pan-PI3K inhibitors to highly selective small molecule isoform-specific inhibitors and emerging degrader (PROTAC) technologies. As first-generation pan-inhibitors faced dose-limiting toxicities, the next wave of R&D is explicitly targeting PTEN-deficient solid tumors (such as prostate and breast cancers), aiming for deep synthetic lethality while sparing the PI3K-alpha driven metabolic pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | AstraZeneca, GSK | PTEN-mutant Prostate/Breast Cancer | Selectivity Assay (Need PIK3CA vs PIK3CB high-purity proteins) |
| PROTACs / Degraders | Emerging Biotechs | Refractory Solid Tumors | Ternary Complex Validation (Need native conformation targets) |
| Combination Therapy | Various | Advanced Solid Tumors (with AR or PARP inhibitors) | Pathway Interrogation (Need Lentivirus for isogenic cell lines) |